Ofatumumab is a feasible alternative anti ‐CD20 therapy in patients intolerant of rituximab
Source: British Journal of Haematology - Category: Hematology Authors: Lucia Y. Chen, Raakhee Shah, Kate Cwynarski, Jonathan Lambert, Christopher McNamara, Sajir G. Mohamedbhai, Andres Virchis, William Townsend, Shirley D'Sa, Kirit M. Ardeshna Tags: Correspondence Source Type: research